Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bempedoic Acid vs Dapagliflozin: Dapagliflozin has the stronger overall evidence (4.4 vs 4.3/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Dapagliflozin wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both Bempedoic Acid and Dapagliflozin have evidence — compare verdict strength side-by-side.
180 mg orally once daily, with or without food, under a clinician. Available alone (Nexletol) or co-formulated with ezetimibe 10 mg (Nexlizet). A prescription drug — dosing is set by a prescriber.
Any time of day
Oral tablet (bempedoic acid 180 mg)
Off-label use mirrors approved dosing (10 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.
Morning
Oral tablet (dapagliflozin)
Weeks (full effect by ~12 weeks)
Months to years
Throughout use
Weeks to months
Weeks
Months to years
Months to years
Weeks to months
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
The New England journal of medicine (2023) · Rct · n=13970
CLEAR Outcomes: ~13,970 statin-intolerant patients randomized to bempedoic acid 180 mg vs placebo
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
The New England journal of medicine (2019) · Rct · n=2230
CLEAR Harmony: 2,230 patients with ASCVD and/or familial hypercholesterolemia on maximally tolerated statins
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
JAMA (2019) · Rct · n=779
CLEAR Wisdom: 779 high-cardiovascular-risk patients on maximally tolerated statins
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
The New England journal of medicine (2019) · Rct · n=4744
DAPA-HF randomized trial in heart failure with reduced ejection fraction
Dapagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2020) · Rct · n=4304
DAPA-CKD randomized trial in a broad, largely non-diabetic chronic-kidney-disease population
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
The New England journal of medicine (2022) · Rct · n=6263
DELIVER randomized trial extending dapagliflozin to mildly reduced and preserved ejection fraction
Dapagliflozin has a higher evidence score (4.4/10 vs 4.3/10) and wins in 2 of 3 categories.
Both Bempedoic Acid and Dapagliflozin score equally (72) for support heart health.
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.